Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

L Arnould, M Gelly, F Penault-Llorca, L Benoit, F Bonnetain, C Migeon, V Cabaret, V Fermeaux, P Bertheau, J Garnier, J-F Jeannin and B Coudert

1Department of Pathology, Centre G-F Leclerc, Dijon 21000, France; 2Centre J Perrin, Clermont 63011, France; 3Department of Surgery, Centre G-F Leclerc, Dijon 21000, France; 4Department of Statistics Centre G-F Leclerc, Dijon 21000, France; 5Centre A Vautrin, Nancy 54000, France; 6Centre O Lambret, Lille 59020, France; 7CHU, Limoges 87000, France; 8CHU Saint Louis, Paris 75010, France; 9Laboratoire Roche, Neuilly 92521, France; 10EPHE, INSERM U517, and IFR 100, Faculté de médecine, Dijon 21000, France; 11Department of Oncology, Centre G-F Leclerc, Dijon 21000, France

This study evaluated by immunohistochemistry (IHC) immune cell response during neoadjuvant primary systemic therapy (PST) with trastuzumab in patients with HER2-positive primary breast cancer. In all, 23 patients with IHC 3+ primary breast cancer were treated with trastuzumab plus docetaxel. Pathological complete and partial responses were documented for nine (39%) and 14 (61%) patients, respectively. Case-matched controls comprised patients treated with docetaxel-based PST without trastuzumab (D; n = 23) or PST without docetaxel or trastuzumab (non-taxane, non-trastuzumab, NT–NT; n = 23). All surgical specimens were blind-analysed by two independent pathologists, with immunohistochemical evaluation of B and T lymphocytes, macrophages, dendritic cells and natural killer (NK) cells. Potential cytolytic cells were stained for Granzyme B and TiA1. HER2 expression was also evaluated in residual tumour cells. Trastuzumab treatment was associated with significantly increased numbers of tumour-associated NK cells and increased lymphocyte expression of Granzyme B and TiA1 compared with controls. This study supports an in vivo role for immune (particularly NK cell) responses in the mechanism of trastuzumab action in breast cancer. These results suggest that trastuzumab plus taxanes lead to enhanced NK cell activity, which may partially account for the synergistic activity of trastuzumab and docetaxel in breast cancer.

British Journal of Cancer (2006) 94, 259–267. doi:10.1038/sj.bjc.6602930 www.bjcancer.com

Published online 10 January 2006

© 2006 Cancer Research UK

Keywords: primary systemic therapy; trastuzumab; ADCC; MoA

The human epidermal growth factor receptor 2 (HER2) is a member of the ErbB family that plays an important role in promoting oncogenic transformation and tumour growth (Slamon et al, 1987). Approximately 25–30% of patients with breast cancer overexpress HER2 and this overexpression is correlated with gene amplification and poor clinical outcome (King et al, 1987; van de Vijver et al, 1992; 1999). Molecular Diagnostics

Patients

Between March 2001 and December 2003, 33 women (age 18–65 years) with stage II/III, unilateral, non-inflammatory, operable
breast cancer requiring a mastectomy (but who wished to conserve the breast) were enrolled in the open-label, multicentre, phase II TAXHER01 trial (Coudert et al, 2005). All patients had HER2-positive (immunohistochemistry (IHC) 3+ or fluorescence in-situ hybridisation (FISH)-positive) breast cancer and were treated with PST consisting of six cycles of docetaxel (100 mg m\(^{-2}\) 60-min intravenous (i.v.) infusion every 3 weeks) and trastuzumab (4 mg kg\(^{-1}\) 90-min i.v. infusion 1 day before the first dose of docetaxel, and thereafter at a dose of 2 mg kg\(^{-1}\) weekly for 17 weeks). All patients underwent surgery 3 weeks after the last cycle of docetaxel and trastuzumab.

In all, 46 patients with breast cancer enrolled in the GIREC01 trial (Luporsi et al, 2000) were used as matched controls. Of these patients, 23 received an anthracycline-based, non-taxane, non-trastuzumab-containing PST (NT–NT; six cycles), and 23 received docetaxel-based, non-trastuzumab-containing therapy (D; six cycles). Tumours from 15 patients in the control group were HER2 positive, five in the NT–NT group and 10 in the D group. The treatment group (TAXHER01) was case-matched with the two control groups in terms of pathologic tumour and node response. Due to the lack of patients treated preoperatively with such a combination, it was not possible to have control groups with different types of chemotherapy, therefore no control groups were used.

Both clinical studies were conducted in accordance with the Helsinki Declaration and approved by an independent ethics committee. Written informed consent was obtained from all patients prior to enrolment.

Microscopic evaluation of the pathologic response to PST

Micromtome sections obtained from surgical tissue were fixed in 10% neutral buffered formaldehyde solution or Bouin fluid (Richard-Allan Scientific, Kalamazoo, MI, USA), embedded in paraffin wax, and stained with haematoxylin, eosin, and saffron. Pathologic response to PST was assessed according to the Sataloff classification (Sataloff et al, 1995). Tumour samples containing no tumour nodules or tumours with residual area < 2 mm in diameter were classified as TA. Tumour samples with residual tumour area < 0.2 mm in diameter in lymph nodes, not classified as micro-metastases in the UCC classification (Singletary et al, 2002; Singletary and Greene, 2003), were classified as NA.

Microscopic and immunohistologic analyses

Immunohistochemical evaluation was performed on one paraffin block that was considered to correspond morphologically with the tumour response area, using the biotin–streptavidin complex (ABC) technique (StreptABC complex/HRP Duet; Dako, Glostrup, Denmark) and the following primary antibodies: B lymphocytes (CD20 (L26, 1 out of 50; Dako, Glostrup, Denmark)); T lymphocytes (CD3 (F7.2.38, 1 out of 25; Dako, Glostrup, Denmark); CD4 (NCL-CD4-368, 1 out of 150; Novocastra, Newcastle, UK); CD8 (CB/144B, 1 out of 25; Dako, Glostrup, Denmark)); macrophages (CD68 (PG-M1, 1 out of 50; Dako, Glostrup, Denmark)); dendritic cells (PS100 (S100, 1 out of 100; Dako, Glostrup, Denmark); CD1a (010, 1 out of 40; Dako, Glostrup, Denmark)); HLA-DR-expressing cells (HLA-DR (TAL.1B5, 1 out of 20; Dako, Glostrup, Denmark)) and natural killer (NK) cells (CD56 (1B6, 1 out of 50; Novocastra, Newcastle, UK); NK1 (NK1, 1 out of 75; Dako, Glostrup, Denmark)). Potential cytolytic cells were stained with Granzyme B (GrB-7, 1 out of 25; Dako, Glostrup, Denmark) and TiA1 (2G9, 1 out of 50; Immunotech, Marseille, France). TiA1 is a 17 kDa cytoplasmic granule-associated protein expressed in cells possessing, like Granzyme B-expressing cells, potential cytolytic activity. If residual tumour cells were identified, immunohistochemical analysis of HER2 expression was performed (A485, 1 out of 1600; Dako, Glostrup, Denmark).

Two pathologists, blinded to study treatment, performed independent IHC evaluations of all tumour samples. Infiltrating cells were analysed in four separate locations on each slide: diffuse (isolated cells distributed all around the area of tumour regression), foci (organised in nodules), around (a small rim around the tumour nodules in contact with residual tumour cells), and inside (penetrating inside tumour nodules between residual tumour cells). In each location on the slide, the number of stained cells was analysed using a semiquantitative ordinal scale ranging from 0 to 4 (0, +/−, +++, +++++). For each antibody, this scale was established after the analysis of more than 15 cases and concerned only the number of infiltrating stained cells, whatever the intensity of the staining. The results of the analyses conducted by each independent pathologist were subsequently compared. For each location, all cases in which scores differed by more than one point on the semiquantitative scale were re-examined and a consensus score was reached.

Statistical analysis

Slides were unblinded immediately prior to the statistical analysis. Statistical analyses were performed with a 5% type I (bilateral) error using the Stata 8.2 software package (StataCorp LP, TX, USA). The mean (standard deviation (s.d.)) number of stained cells was calculated for each data group (treatment group and two control groups). A two-sided Wilcoxon rank-sum (Mann–Whitney) test was used to determine differences between the groups.

A subgroup analysis was also performed to exclude potential treatment-independent, HER2 overexpression-related effects if values obtained for the treatment and control groups were significantly different. This analysis compared the results from the treatment group (TAXHER01) with those from HER2-overexpressing subgroups of the control groups (HER2 control, n = 15). Due to multiple testing, a type I error adjustment was applied to this subgroup analysis (significance level P ≤ 0.01).

RESULTS

Three patients from the TAXHER01 trial withdrew from the study due to toxicity. Seven additional cases were not available for immunohistochemical analysis because of fixative problems or

|               | TAXHER01 (N = 23) | NT-NT (N = 23) | D (N = 23) |
|---------------|-------------------|----------------|-----------|
| Age, mean (range) | 45 (24–64) | 44.5 (27–60) | 47.5 (27–65) |
| Clinical tumour stage | T2 14 | 16 | 13 |
|                | T3 9 | 7 | 10 |
| Clinical nodal status | N0 10 | 10 | 10 |
|               | N1 13 | 13 | 13 |
| Scarff-Bloom-Richardson tumour grade | I 1 | 3 | 1 |
|               | II 9 | 9 | 8 |
|               | III 13 | 11 | 14 |
| Tumour hormone-receptor status | Positive 13 | 12 | 13 |
|               | Negative 10 | 11 | 10 |
| NT-NT = non-taxane, non-trastuzumab; D = docetaxel.
In-vivo evidence of ADCC role in trastuzumab MoA
L Arnould et al
British Journal of Cancer (2006) 94(2), 259 – 267
© 2006 Cancer Research UK

Table 2  Immune cell infiltration into breast tumours following PST

| Antibodies location | Mean (s.d) staining intensity score | P-value |
|---------------------|------------------------------------|---------|
| Diffuse             |                                    |         |
| CD20                |                                    |         |
| 1.61 (1.3)          | 1.10 (0.9)                         | 1.09 (0.9) 1.04 (0.9) | 0.0802 | 0.8272 |
| 1.13 (1.5)          | 0.52 (1.2)                         | 0.39 (1.0) 0.65 (1.3) | 0.0598 | 0.4432 |
| 0.43 (0.9)          | 0.33 (0.9)                         | 0.04 (0.1) 0.61 (1.2) | 0.4013 | 0.0686 |
| 3.12 (1.2)          | 1.70 (1.5)                         | 1.61 (1.4) 1.78 (1.7) | 0.0005 | 0.8991 |
| Diffuse             |                                    |         |
| D                   |                                    |         |
| 0.45 (1.3)          | 0.33 (0.9)                         | 0.04 (0.1) 0.61 (1.2) | 0.4013 | 0.0686 |
| 0.95 (1.5)          | 0.52 (1.2)                         | 0.39 (1.0) 0.65 (1.3) | 0.0598 | 0.4432 |
| 3.12 (1.2)          | 1.70 (1.5)                         | 1.61 (1.4) 1.78 (1.7) | 0.0005 | 0.8991 |
| Diffuse             |                                    |         |
| NT–NT               |                                    |         |
| 0.45 (1.3)          | 0.33 (0.9)                         | 0.04 (0.1) 0.61 (1.2) | 0.4013 | 0.0686 |
| 0.95 (1.5)          | 0.52 (1.2)                         | 0.39 (1.0) 0.65 (1.3) | 0.0598 | 0.4432 |
| 3.12 (1.2)          | 1.70 (1.5)                         | 1.61 (1.4) 1.78 (1.7) | 0.0005 | 0.8991 |
| Diffuse             |                                    |         |
| TAXHER01 vs control |                                    |         |
| 0.45 (1.3)          | 0.33 (0.9)                         | 0.04 (0.1) 0.61 (1.2) | 0.4013 | 0.0686 |
| 0.95 (1.5)          | 0.52 (1.2)                         | 0.39 (1.0) 0.65 (1.3) | 0.0598 | 0.4432 |
| 3.12 (1.2)          | 1.70 (1.5)                         | 1.61 (1.4) 1.78 (1.7) | 0.0005 | 0.8991 |
| Diffuse             |                                    |         |
| D vs NT–NT          |                                    |         |
| 0.45 (1.3)          | 0.33 (0.9)                         | 0.04 (0.1) 0.61 (1.2) | 0.4013 | 0.0686 |
| 0.95 (1.5)          | 0.52 (1.2)                         | 0.39 (1.0) 0.65 (1.3) | 0.0598 | 0.4432 |
| 3.12 (1.2)          | 1.70 (1.5)                         | 1.61 (1.4) 1.78 (1.7) | 0.0005 | 0.8991 |

NT–NT, anthracycline-based PST that does not include a taxane or trastuzumab; D, docetaxel-based PST. For diffuse/around/inside/foci, scores range from 0 to 4. *Staining with CD56 was less intense and difficult to quantify. Significant if P < 0.05. Bold values signify their importance in the results and the discussion.
false-positive HER2 overexpression. The final analysis was therefore performed on the surgical specimens from 23 patients. The control group from the GIREC01 trial comprised specimens obtained from 46 (23 NT–NT and 23 D) patients, 15 of whom had tumours that were HER2 positive (5 NT–NT and 10 D). Patient characteristic data are shown in Table 1.

Pathologic response

After surgery, nine tumours in the TAXHER01 group (39%) were classified as demonstrating a pathological complete response (pCR; TA/NA or TA/NB), with two demonstrating residual tumour aggregates < 2 mm in diameter. One other tumour was classified as TA/NC (no residual tumour in the breast, but residual tumour cells in the lymph nodes). The remaining 13 tumours displayed partial (pPR; TB or TC) or absent (TD) pathological responses. Eight tumours were classified as TB (residual tumour size 0.4–1.5 cm (mean 0.80 cm)), four were classified as TC (residual tumour size 1.5–7.0 cm (mean 3.2 cm)), and only one tumour was classified as TD (residual tumour size 6 cm). As tumour responses in the two control groups were matched to those in the treatment group, there were equivalent numbers of patients with complete, partial, or absent pathological responses in the 23 tumours treated in the D and NT–NT groups.

Areas of tumour response were associated with fibrosis, myxoedema, and macrophage/lymphocyte infiltration. Necrosis or infiltration with polynuclear neutrophils was not observed.

Immunohistochemical analysis

Immune cell infiltration

Comparison of the three groups revealed that higher expression of PS100 and HLA-DR was observed in the TAXHER01 and NT–NT groups as compared with the D group, although the difference was not statistically significant (Table 2). Comparison of pooled results from the D and NT–NT groups with TAXHER01 showed greater numbers of immunocompetent cells in the TAXHER01 specimens compared with controls. B lymphocytes were more numerous in the TAXHER01 specimens at the four locations analysed, but the difference was only significant in the foci infiltrates. T lymphocytes (CD3, CD4, and CD8) were also more numerous in the TAXHER01 specimens; differences between TAXHER01 and control specimens were statistically significant in the diffuse and foci infiltrates for CD3, in the foci, inside and around infiltrates for CD4, and in the foci and around infiltrates for CD8. Tumour area infiltration by macrophages (CD68) was not statistically different between the TAXHER01 and
control groups. Dendritic cells (PS100, CD1a) and HLA-DR-expressing inflammatory cells appeared to be slightly more abundant in the TAXHER01 samples, but, because of the differences between the two control groups, results are difficult to interpret (Table 2). Figures 1–4 show immunohistochemical staining of cells that are able to undergo ADCC mechanisms, and that have potential cytotoxic activity, from both the TAXHER01 group and the case-matched control groups. Natural killer cell numbers were increased in the around (Figure 1A) and inside infiltrates of residual tumour cells in TAXHER01 specimens compared with controls (statistically significant by NK1 staining, Figure 1). In addition, there were statistically more NK1-positive cells in foci infiltrates from TAXHER01 specimens compared with controls. Staining with CD56 is notoriously difficult and was therefore less intense than other methods and consequently difficult to quantify (Figure 2). Finally, cytotoxic molecule (Granzyme B and TiA1)-expressing cells were more numerous in contact with the residual tumour cells in TAXHER01 specimens compared with controls (Figures 3 and 4), with statistically significant differences demonstrated for Granzyme B (around) and for TiA1 (inside).

Influence of HER2 overexpression on immune cell infiltration

To evaluate the potential treatment-independent effects of HER2 overexpression, immune cell infiltration in TAXHER01 tumours was compared with that in HER2-positive tumour subgroups of the control groups (HER2 control, n = 15) (Table 3). While the number of cases in the HER2-positive tumour subgroup is low, the comparison between the TAXHER01 treatment group and this subgroup is favoured as these tumour samples were obtained from a clinical trial and hence had validated clinical and pathological data.

The limited number of cases in this subanalysis precludes definitive conclusions. There was a trend towards increased lymphocyte numbers (CD20, CD3, CD4, and CD8) in the TAXHER01 group compared with HER2 controls. Diffuse macrophage infiltration (CD68) was significantly increased in HER2 controls compared with the treatment group, but increased macrophage infiltration was observed around the residual tumours in the treatment group. There was also a trend towards increased dendritic cell (PS100, CD1a) and HLA-DR-expressing cell infiltration in TAXHER01 tumours. Natural killer and cytotoxic cells (TiA1 or Granzyme B) tended to be more numerous in contact with residual tumour cells in the TAXHER01 tumours, with significant differences demonstrated for TiA1 ($P < 0.05$) and NK1 staining ($P < 0.01$).

**Figure 3** Immunohistochemical staining with Granzyme B. Residual tumour from the TAXHER01 group (A) and from a matched tumour treated in the control group (B), both stained with Granzyme B. The tumours of the TAXHER01 group show more cells in contact with or close to the tumour cells.

**Figure 4** Immunohistochemical staining with TiA1. Residual tumour from the TAXHER01 group (A) and from a matched tumour treated in the control group (B), both stained with TiA1. The tumours of the TAXHER01 group show more cells in contact with or close to the tumour cells.
**Table 3** Immune cell infiltration into HER2-overexpressing breast tumours following PST

| Antibodies location | Mean (s.d.) staining intensity score | P-value |
|---------------------|-------------------------------------|---------|
| **TAXHER01**        | **HER2 control**                    |         |
| **(n = 23)**        | **(n = 15)**                        |         |
| **CD20**            | CD20                                |         |
| Diffuse             | 1.61 (1.27)                         | 1.53 (1.19) | 0.8525 |
| Around              | 1.13 (1.52)                         | 0.40 (1.06) | 0.1036 |
| Inside              | 0.43 (0.94)                         | 0.20 (0.77) | 0.2488 |
| Foci                | 3.13 (1.18)                         | 2.13 (1.64) | 0.0840 |
| **CD3**             | CD3                                 |         |
| Diffuse             | 2.09 (1.41)                         | 1.80 (1.08) | 0.3734 |
| Around              | 1.52 (1.62)                         | 0.93 (1.44) | 0.2352 |
| Inside              | 0.65 (1.19)                         | 0.40 (0.74) | 0.6948 |
| Foci                | 2.87 (1.06)                         | 1.67 (1.40) | 0.0046 |
| **CD4**             | CD4                                 |         |
| Diffuse             | 1.04 (1.33)                         | 0.87 (0.91) | 0.9618 |
| Around              | 1.35 (1.67)                         | 0.33 (0.72) | 0.0605 |
| Inside              | 0.35 (0.71)                         | 0.00 (0.00) | 0.0565 |
| Foci                | 2.17 (1.27)                         | 1.53 (1.30) | 0.1423 |
| **CD8**             | CD8                                 |         |
| Diffuse             | 1.96 (1.49)                         | 2.00 (1.00) | 0.9259 |
| Around              | 1.56 (1.70)                         | 0.80 (1.21) | 0.1342 |
| Inside              | 1.22 (1.31)                         | 0.67 (0.90) | 0.2039 |
| Foci                | 2.39 (1.62)                         | 2.33 (1.17) | 0.5882 |
| **CD56**            | CD56                                |         |
| Diffuse             | 1.91 (1.31)                         | 3.13 (0.74) | **0.0037** |
| Around              | 0.91 (1.59)                         | 0.00 (0.00) | 0.0341 |
| Inside              | 0.56 (0.99)                         | 0.33 (0.72) | 0.5592 |
| Foci                | 0.09 (0.42)                         | 0.00 (0.00) | 0.4193 |
| **PS100**           | PS100                               |         |
| Diffuse             | 1.70 (1.29)                         | 2.00 (1.07) | 0.4600 |
| Around              | 1.35 (1.64)                         | 0.67 (1.29) | 0.2253 |
| Inside              | 0.61 (1.31)                         | 0.20 (1.56) | 0.4394 |
| Foci                | 1.74 (1.66)                         | 1.27 (1.53) | 0.3246 |
| **CD1a**            | CD1a                                |         |
| Diffuse             | 1.61 (0.78)                         | 1.80 (0.77) | 0.4990 |
| Around              | 0.39 (0.72)                         | 0.40 (0.91) | 0.7624 |
| Inside              | 0.26 (0.54)                         | 0.27 (0.80) | 0.5800 |
| Foci                | 0.00 (0.00)                         | 0.00 (0.00) | 0.9999 |
| **HLA-DR**          | HLA-DR                              |         |
| Diffuse             | 2.09 (1.04)                         | 2.40 (0.91) | 0.5216 |
| Around              | 1.69 (1.72)                         | 0.73 (1.33) | 0.0786 |
| Inside              | 0.91 (1.16)                         | 0.53 (0.92) | 0.3676 |
| Foci                | 2.30 (1.15)                         | 2.00 (1.20) | 0.5809 |
| **CD56**            | CD56                                |         |
| Diffuse             | 0.83 (1.03)                         | 0.67 (0.82) | 0.7562 |
| Around              | 1.00 (1.51)                         | 0.80 (1.08) | 0.8762 |
| Inside              | 0.30 (0.70)                         | 0.20 (0.56) | 0.7062 |
| Foci                | 0.26 (0.69)                         | 0.53 (1.12) | 0.4797 |
| **NK1**             | NK1                                 |         |
| Diffuse             | 1.45 (1.40)                         | 1.20 (0.86) | 0.5737 |
| Around              | 1.64 (1.56)                         | 0.40 (1.12) | **0.0097** |
| Inside              | 0.82 (1.26)                         | 0.20 (0.77) | **0.0532** |
| Foci                | 2.05 (1.45)                         | 1.07 (1.16) | **0.0303** |
| **TA1**             | TA1                                 |         |
| Diffuse             | 1.13 (1.32)                         | 1.67 (0.82) | 0.1448 |
| Around              | 1.43 (1.73)                         | 0.53 (1.41) | 0.0942 |
| Inside              | 0.65 (1.03)                         | 0.07 (0.26) | **0.0407** |
| Foci                | 1.00 (1.20)                         | 1.00 (1.51) | 0.8120 |

**Table 3** (Continued)

| Antibodies location | Mean (s.d.) staining intensity score | P-value |
|---------------------|-------------------------------------|---------|
| **TAXHER01**        | **HER2 control**                    |         |
| **(n = 23)**        | **(n = 15)**                        |         |
| **(n = 15)**        | **(n = 15)**                        |         |
| **CD1a**            | CD1a                                |         |
| Diffuse             | 1.10 (1.32)                         | 1.80 (1.08) | 0.5737 |
| Around              | 1.43 (1.73)                         | 0.40 (1.12) | **0.0097** |
| Inside              | 0.82 (1.26)                         | 0.20 (0.77) | **0.0532** |
| Foci                | 2.05 (1.45)                         | 1.07 (1.16) | **0.0303** |

**DISCUSSION**

Approximately 20–30% of all breast cancers overexpress HER2 (Slamon et al., 1987; van de Vijver et al., 1988; Ross et al., 2003; Owens et al., 2004). Targeted treatment of HER2-positive metastatic breast cancer (MBC) with single-agent trastuzumab demonstrates favourable efficacy (Cobleigh et al., 1999; Vogel et al., 2002), and efficacy is enhanced by combination with cytotoxic chemotherapy (Slamon et al., 2001; Marty et al., 2005). Indeed, combination treatment with trastuzumab and cytotoxic chemotherapy is now used as standard therapy for HER2-positive MBC. Trastuzumab is thought to have a diverse and complex mechanism of action. As trastuzumab is a monoclonal antibody that binds to the surfaces of HER2-overexpressing cancer cells, it has been postulated that ADCC may play an important role in the mechanism of action of this drug (Cooley et al., 1999; Clynes et al., 2000; Carson et al., 2001; Repka et al., 2003; Gennari et al., 2004). The current in vivo study was undertaken to analyse the potential role of different immune cells in the clinical response to trastuzumab.

Pre- and postoperative breast tissue samples were obtained from patients with HER2-overexpressing advanced breast cancer participating in a clinical trial of a neoadjuvant regimen incorporating trastuzumab and docetaxel. This treatment strategy is associated with a high pathologic response rate (Coudert et al., 2005), which is in accordance with the good efficacy previously reported for the combination of paclitaxel and trastuzumab in this setting (Bines et al., 2003; Burstein et al., 2003; Schiffhauer et al., 2003; Van Pelt et al., 2003; Baselga et al., 2004). In order to discount the effects of intratumoural immune cell modifications that may be induced by conventional chemotherapy drugs, the control group comprised tumours from patients treated with two different PST.
Table 4 Immune cell infiltration into breast tumours following trastuzumab-based PST by response status

| Antibodies location | Mean (s.d.) staining intensity score | P-value |
|---------------------|-------------------------------------|---------|
| **CD20**            |                                     |         |
| Diffuse             | 1.50 (1.51)                         | 1.0000  |
| Around              | 2.75 (1.28)                         | 0.0187  |
| Inside              | 1.13 (1.36)                         | 0.2090  |
| Foci                | 3.63 (0.52)                         | 0.7339  |
| **CD3**             |                                     |         |
| Diffuse             | 1.50 (1.41)                         | 0.9381  |
| Around              | 3.25 (0.71)                         | 0.0362  |
| Inside              | 1.75 (1.49)                         | 0.0437  |
| Foci                | 3.00 (0.76)                         | 0.6134  |
| **CD4**             |                                     |         |
| Diffuse             | 0.88 (1.64)                         | 0.7659  |
| Around              | 2.75 (1.49)                         | 0.1852  |
| Inside              | 0.75 (1.04)                         | 0.6737  |
| Foci                | 2.50 (1.13)                         | 0.9364  |
| **CD8**             |                                     |         |
| Diffuse             | 2.13 (1.36)                         | 0.0203  |
| Around              | 2.88 (1.25)                         | 0.7362  |
| Inside              | 1.75 (1.04)                         | 0.0503  |
| Foci                | 2.38 (1.69)                         | 0.7045  |
| **CD68**            |                                     |         |
| Diffuse             | 0.88 (1.25)                         | 0.0467  |
| Around              | 2.13 (1.81)                         | 0.2590  |
| Inside              | 0.88 (1.25)                         | 0.6215  |
| Foci                | 0.25 (0.71)                         | 0.4292  |
| **PS100**           |                                     |         |
| Diffuse             | 1.50 (1.51)                         | 0.3635  |
| Around              | 2.25 (1.58)                         | 0.6471  |
| Inside              | 1.50 (1.85)                         | 0.2418  |
| Foci                | 1.75 (1.91)                         | 0.5323  |
| **CD1a**            |                                     |         |
| Diffuse             | 1.50 (0.93)                         | 0.4666  |
| Around              | 0.88 (0.83)                         | 0.2590  |
| Inside              | 0.63 (0.74)                         | 0.2693  |
| Foci                | 0.00 (0.00)                         | 0.0000  |
| **HLA-DR**          |                                     |         |
| Diffuse             | 2.00 (1.31)                         | 0.8750  |
| Around              | 3.13 (1.36)                         | 0.1454  |
| Inside              | 1.75 (1.04)                         | 0.6471  |
| Foci                | 2.50 (1.31)                         | 1.0000  |
| **CD56**            |                                     |         |
| Diffuse             | 0.75 (1.16)                         | 0.5306  |
| Around              | 2.25 (1.67)                         | 0.1460  |
| Inside              | 0.88 (0.99)                         | 0.0714  |
| Foci                | 0.00 (0.00)                         | 0.2059  |
| **NK1**             |                                     |         |
| Diffuse             | 0.57 (1.13)                         | 0.6282  |
| Around              | 3.00 (1.41)                         | 0.1063  |
| Inside              | 1.29 (1.50)                         | 1.0000  |
| Foci                | 2.71 (1.38)                         | 0.2332  |
| **TA1**             |                                     |         |
| Diffuse             | 0.63 (1.19)                         | 0.5902  |
| Around              | 3.13 (1.36)                         | 0.0456  |
| Inside              | 1.50 (1.20)                         | 0.1697  |
| Foci                | 0.50 (1.41)                         | 0.8160  |

Further support for a role for ADCC in the mechanism of action of trastuzumab has emerged from in vivo xenograft (Clynes et al., 2000) and in vitro studies (Cooley et al., 1999; Carson et al., 2001; Kubo et al., 2003), which have demonstrated that NK cells are able to kill trastuzumab-coated HER2-overexpressing cells via a FcγRIII receptor (CD16)-mediated ADCC mechanism. Yamaguchi et al. (2005) also demonstrated that lymphokine-activated killer cell cytotoxic activity against HER2-positive breast cancer cell lines MDA-MB453 and ZR75-1 was significantly increased in the presence of 10 nM trastuzumab. These data, together with the current data, lend support to the evaluation of combination regimens (including and excluding docetaxel). Treatment and control groups were matched in respect of pathologic response to eliminate the effects of intratumoral immune cell modifications induced by the response itself. This is the first time a comparison of this type has been reported.

The results of this study demonstrate that the inclusion of trastuzumab in the PST regimen influences the number and topography of various immune cells, including T and B lymphocytes and NK cells, in tumour infiltrates. Natural killer cells are able to kill cells that are coated with an antibody via an ADCC mechanism (Clynes et al., 2000). The presence of increased numbers of NK cells in tumour infiltrates after trastuzumab treatment, as well as the presence of cytotoxic proteins such as Granzyme B, lends support to a role for NK cells in trastuzumab-induced tumour regression. Increased numbers of NK cells are also seen in tumours demonstrating an incomplete but pathologically important response (TB) compared with those showing a poor or absent pathologic response (TC or TD). The persistence of HER2 overexpression confirms that trastuzumab-mediated ADCC is a feasible mechanism of action for the drug.

Two in vivo pilot studies have evaluated the potential role of ADCC in the mechanism(s) of action of trastuzumab. Repka et al. (2003) demonstrated that treatment with a combination of trastuzumab and interleukin-2 led to NK cell expansion and NK cell-mediated ADCC against HER2-overexpressing cells. Additionally, they showed that serum from treated patients had residual ADCC activity 2–8 weeks after the last trastuzumab injection. Gennari et al. (2004) showed that peripheral blood mononuclear cells of trastuzumab-treated patients demonstrated in vitro cytotoxic activity against HER2-overexpressing cells, with ADCC activity more pronounced in tumours demonstrating a good response compared with those exhibiting a poor response. In common with the present study, Gennari did not observe downregulation of HER2 expression after treatment, although they were able to demonstrate that residual tumour cells were still coated with trastuzumab at the time of the surgery as well as an increase in NK-rich lymphoid infiltration, but were unable to attribute this increase to the type of treatment or to the regression itself.

Further support for a role in ADCC in the mechanism of action of trastuzumab has emerged from in vivo xenograft (Clynes et al., 2000) and in vitro studies (Cooley et al., 1999; Carson et al., 2001; Kubo et al., 2003), which have demonstrated that NK cells are able to kill trastuzumab-coated HER2-overexpressing cells via a FcγRIII receptor (CD16)-mediated ADCC mechanism. Yamaguchi et al. (2005) also demonstrated that lymphokine-activated killer cell cytotoxic activity against HER2-positive breast cancer cell lines MDA-MB453 and ZR75-1 was significantly increased in the presence of 10 nM trastuzumab. These data, together with the current data, lend support to the evaluation of combination...
therapy with trastuzumab and immunomodulatory agents, such as interleukin-2 (Fleming et al., 2002; Repka et al., 2003), as well as the construction of bispecific antibodies targeting HER2 and CD16 (Shahied et al., 2004).

Trastuzumab plus docetaxel is an approved and well-tolerated anticancer regimen that is used worldwide for the treatment of HER2-positive MBC. Taxanes, especially docetaxel, lead to increased serum concentrations of some cytokines and enhancement of NK cell activity (Tsavaris et al., 2002). The current study confirms that NK cytotoxicity via ADCC is probably one of the mechanisms of action of trastuzumab and demonstrates increased numbers of NK cells in tumours treated with docetaxel and trastuzumab compared with docetaxel alone. These findings may partially explain the synergistic activity of trastuzumab and docetaxel in the treatment of HER2-positive breast cancer and the excellent clinical outcomes afforded by this combination. In the TAXHER01 study (Coudert et al., 2005), tumours that were centrally confirmed to be HER2 positive displayed a pCR of 54%.

This is superior to that observed with non-trastuzumab-containing neoadjuvant regimens in unselected patient populations. The results of this immunohistochemical study may also have implications for the design of future clinical trials involving trastuzumab. Perceived trastuzumab activity may be damaged by association with therapies that have immunosuppressive properties. An interesting area for future investigation could be combination therapy with trastuzumab, chemotherapy and immunomodulators, for example, co-administration of NK cells and/or cytokine injections.

ACKNOWLEDGEMENTS

This work was presented in part at the 96th AACR Annual Meeting, April 2005, and was supported in part by the Comités de Côte d’Or et de la Nièvre de la Ligue contre le Cancer and by F Hoffmann-La Roche Ltd.
Pegram M, Hsu S, Lewis G, Pietras R, Berty M, Sliwkowski M, Goombs D, Baly D, Kabbinavar F, Slamon D (1999) Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18: 2241–2251

Repka T, Chiorean EG, Gay J, Herwig KE, Kohl VK, Yee D, Miller JS (2003) Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study. Clin Cancer Res 9: 2440–2446

Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Puziat L, Bloom KJ (2003) The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8: 307–325

Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z (1995) Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 180: 297–306

Schiffhauer LM, Griggs JJ, Ahrendt GM, Sorbero ME (2003) Docetaxel and trastuzumab as primary systemic therapy for HER-2/neu-overexpressing breast cancer. Proc Am Soc Clin Oncol 22: 242 (abstract 969)

Shahied LS, Tang Y, Alpaugh RK, Somer R, Greenspon D, Weiner LM (2004) Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumour lysis when placed in a divalent tumour antigen-binding format. J Biol Chem 279: 53907–53914

Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL (2002) Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 20: 3628–3636

Singletary SE, Greene FL (2003) Breast task force: revision of breast cancer staging: the 6th edition of the TNM Classification. Semin Surg Oncol 21: 53–59

Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182

Slamon DJ, Godolphin W, Jones LA, Holt JA, Wang SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707–712

Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–792

Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P, Boulamatsis D (2002) Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 87: 21–27

van de Vijver MJ, Perou CM, Golub TR, van de Vijver MJ, Perou CM, Golub TR, van de Vijver MJ, Perou CM, Golub TR (1997) A Fortuitous Gene with Anticancer Properties as a Marker of Breast Cancer Prognosis. Nature Medicine 3: 419–425

Van Pelt AE, Moshis S, Elledge RM, Hilsenbeck SG, Gutierrez MC, Lucci Jr A, Kalidas M, Granch T, Scott BG, Allred DC, Chang JC (2003) Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin Breast Cancer 4: 348–353

Vogel CL, Cobleigh MA, Tripathy D, Gheitel JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart S, Press M (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719–726

Yakes FM, Chirntranalab W, Ritter CA, King W, Seelig S, Arteaga CL (2002) Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumour action. Cancer Res 62: 4132–4141

Yamaguchi Y, Hironaka K, Okawaki M, Oikawa M, Matsuura K, Ohshita A, Toje T (2005) HER2-specific cytotoxic activity of lympholine-activated killer cells in the presence of trastuzumab. Anticancer Res 25: 827–832